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Background: At the time of diagnosis, more than 50% of patients with myelodysplastic syn-
drome have a normal karyotype and are classiﬁed as having a favorable prognosis. However,
these patients often show very variable clinical outcomes. Furthermore, current diagnostic
tools lack the ability to look at genetic factors beyond karyotyping in order to determine the
cause of this variability.
Objective: To evaluate the impact of p53 protein expression at diagnosis in patients with
low-risk myelodysplastic syndrome.
Methods: This study enrolled 38 patients diagnosed with low-risk myelodysplastic
syndrome. Clinical data were collected by reviewing medical records, and immunohisto-
chemical p53 staining was performed on bone marrow biopsies.
Results: Of the 38 participants, 13 (34.21%) showed p53 expression in their bone marrow.
At diagnosis, this group of patients also presented clinical features characteristic of a poor
prognosismore often than patientswho did not express p53. Furthermore, patients express-
ing p53 had a shorter median survival time compared to those without p53 expression.
Conclusion: This study shows that the expression of p53 at diagnosis is a useful indicator
of distinct clinical characteristics and laboratory proﬁles found in low-risk myelodysplastic
syndrome patients. These data indicate that the immunohistochemical analysis of p53 may
be a prognostic tool for myelodysplastic syndrome and should be used as an auxiliary test
to help determine the best therapeutic choice.o Bra© 2014 Associac¸ã∗ Corresponding author at: Rua Capitão Francisco Pedro, 1210 Rodolfo
(UFC), 60430-370 Fortaleza, CE, Brazil.
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yelodysplastic syndrome (MDS) is the general term used
o deﬁne diseases affecting clonal hematopoietic progeni-
or cells. Patients with a MDS disease often have ineffective
ematopoiesis, cytopenias, blood cell dysplasia (of one or
ore cell types), and are at high risk for developing acute
yeloid leukemia (AML).1 In order to effectively treat MDS
atients, the International Prognostic Scoring System (IPSS)
s used as a risk stratiﬁcation tool and is utilized to estimate
atient survival and time until the development of AML. Since
ts release in 1997, the IPSS has become the standard clini-
al tool for risk assessment of newly diagnosed MDS patients.
sing this tool, patients are stratiﬁed based on the percentage
f bone marrow blasts, number of cytopenias, and the patient
aryotype at diagnosis. These data help to rank the patient
nto one of four distinct categories: low risk, intermediate risk
, intermediate risk II (intermediate prognosis), and high risk
unfavorable prognosis).2,3
Although the IPSS is a valuable tool, several limitations
ave become evident over time including a relative over-
epresentation of blast percentage, under-representation of
ytogenetic abnormalities, and an underestimation of risk for
ome patients, particularly those with severe cytopenias or a
ormal karyotype. A recently published revision of the IPSS,
hat is the IPSS-R,4 addresses some of these deﬁciencies. Most
mportantly, the IPSS-R considers amuch larger set of chromo-
omal abnormalities and better stratiﬁes the prognostic risk
ssociated with them. The revised version also decreases the
elative weight of bone marrow blasts, with blast proportions
etween 2% and 5% being recognized as adverse and consid-
rs cytopenias individually, weighing their severity instead of
ust their presence. Finally, the IPSS-R also assigns patients to
ne of ﬁve risk groups instead of just four, as described in the
riginal IPSS.5
However, the IPSS-R does not address the chromosomal
ariability observed in MDS patients. At diagnosis, more than
0% of patients with MDS have a normal karyotype and
re typically classiﬁed as having a more favorable progno-
is; however, these patients often show very variable clinical
utcomes.6 Thus, studying other markers is particularly
mportant as it provides information beyond the patient’s
aryotype, allowing clinicians to better characterize patient
rognosis, especially for those with a normal karyotype.1 For
xample, the tumor suppressor protein, p53, known for its
ole in cell cycle arrest, apoptosis, and proliferation associ-
ted with malignant tumor progression, has been identiﬁed as
key factor in phenotypic variability in a MDS mouse model.7
he objective of this study was to evaluate the impact of p53
rotein expression on the phenotypic characteristics and the
isk of progression to AML in patients with low-risk MDS.
ethodsatients
his study enrolled 38 low-risk adult MDS patients of both
enders at a specialized clinic in Fortaleza, Ceará, Brazil. The14;36(3):196–201 197
diagnosis of MDS was performed according to the minimum
diagnostic criteria established by the 2006 Conference on MDS
held in Vienna.8 By consensus, the minimal diagnostic criteria
include the following:markedand constant peripheral cytope-
nia (>6 months) of at least one major hematopoietic lineage,
MDS-related bone marrow features (i.e. one or more of the
following in at least one major hematopoietic lineage: dys-
plasia≥10%, ring sideroblasts≥15%, or myeloblasts≥5%), or
an MDS-related karyotype. Furthermore, all other hematopoi-
etic and non-hematopoietic disordersmust be ruled out as the
primary reason for the dysplasia and/or cytopenia.
The patient group consisted of nine (23.7%) men and 29
(76.3%) women, with ages ranging from 47 to 95 years and a
median age of 61. Patients eligible for this studywere classiﬁed
as having low-risk MDS according to the IPSS-R.6
This study was approved by the Ethics Committee of the
Universidade Federal do Ceará (UFC), and informed consent
was obtained from all patients.
Data collection, sample processing, and clinical follow-up
Clinical data related to age, blood count, and bone marrow
biopsy at diagnosis were collected by analyzing the patient’s
medical records.
Immunohistochemical analysis
Immunohistochemical analysis of p53 was performed accord-
ing to the procedure described by Kitagawa et al.9 Bone
marrow biopsy sections from each patient were decalciﬁed
using 10% nitric acid and were parafﬁn embedded prior
to immunohistochemical analysis. Then, the bone marrow
sections were deparafﬁnized, hydrated, and washed with
buffered saline (pH 7.0). Antigen retrieval was then performed
using a 10mM citrate buffer (pH 6.0) for 30min, and the sec-
tions were subsequently blocked with two cycles of treatment
with a methanol solution containing an endogenous peroxi-
dase and0.03%hydrogenperoxide for 5min each. The sections
were subsequently incubated with a monoclonal antibody
speciﬁc for p53 (Clone DO-7; DAKO) for 12h at 4 ◦C. The slides
were washed with buffered saline and incubated for 1h with
biotinylated IgG antibody after which the sections were again
washed with buffered saline and incubated with the ABC
complex (DAKO) for 45min. The ABC complex contains 5L
of avidin and 5L of biotin in 5mL of buffered saline. To
visualize the reaction, the slides were treated with 1mg/mL
diaminobenzidine (DAKO) solution, followed by counter stain-
ing with hematoxylin. Cover slips were mounted on slides
using Canada balsam. The p53 protein expression was deﬁned
as being positive or negative based on the level of nuclear
staining. Positive levels were indicated when at least 1% of
the hematopoietic cells showed nuclear staining.
Statistical analysis
Results are expressed as means± standard error. Data anal-
ysis was performed using the GraphPad Prism 5.0 statistics
program. The Kolmogorov–Smirnov test was used to check
for normal distribution of the data, and statistical differ-
ences between groups were observed using a t-test or the
198 rev bras hematol hemoter. 2014;36(3):196–201
Table 1 – Clinical characteristics of patients grouped according to their p53 expression at diagnosis.
Parameters p53 expression p-Value
Negative (n=25) Positive (n=13)
Mean age (years±SE) 54.78±3.55 66.88±5.15 0.0341
Gender – n (%)
Male 6 (24) 4 (30.8) >0.05
Female 19 (76) 9 (69.2)
Median duration of MDS (months±SE) 22.33±15.32 32.52±24.49 >0.05
Cytogenetics – n (%)
Normal karyotype 24 (96) 11 (84.7) >0.05
Chromosomal aberrations 1 (4)a 2 (15.3)b
IPSS – n (%)
Low 23 (92) 7 (53.8) 0.011
Intermediate-1 2 (8) 6 (46.2)
IPSS-R – n (%)
Very low 22 (88) 11 (84.7) >0.05
Low 3 (12) 2 (15.3)
Complete blood count (±SE)
Hemoglobin (g/L) 111.7±0.62 95.41±0.44 0.038
Hematocrit (%) 33.86±1.66 29.91±1.82 0.043
MCV (fL) 89.10±2.98 87.70±2.70 >0.05
Leukocytes (×109/L) 5.23±711.2 3.25±349.9 0.031
Platelets (×109/L) 248.2±47.66 215.7±35.30 >0.05
Treatment – n (%)
Azacitidinec 1 (2.6) 0 (0) NA
Lenalidomided 0 (0) 1 (2.6) NA
Azacitidine+ lenalidomided 0 (0) 1 (2.6) NA
SE: standard error; MDS: myelodysplastic syndromes; IPSS: International Prognostic Scoring System; IPSS-R: Revised International Prognostic
Scoring System.
a Chromosomal aberrations detected: del 5q.
b Chromosomal aberrations detected: del 5q and iso (17).
solati
puscular volume (MCV) was also analyzed for each patient,
and the mean level found for p53-positive patients was sim-
ilar to that found for p53-negative patients (p-value>0.05).c Treatment recommended because of severe thrombocytopenia in i
d Treatment used during progression to AML.
Mann–Whitney test. A Kaplan–Meier curve was constructed,
and the log-rank test was applied to verify statistical dif-
ferences between the times of combined event-free survival
(progression to AML or death). The combined event-free
survival was deﬁned as the time interval between date of
diagnosis and date of the ﬁrst negative event (death related
to disease progression or progression to AML). The level of
signiﬁcance was set for a p-value<0.05 in all analyses.
Results
Table 1 shows the clinical characteristics for patients aswell as
their status for p53 expression at diagnosis. Of the 38 patients
who participated in the study, 13 (34.21%) showed p53 pro-
tein expression in the nuclei of hematopoietic cells from their
bone marrow (Figure 1). Interestingly, p53 expression appears
to be correlated with a higher age at diagnosis (66.88 years),
while patients who were diagnosed at a younger age (54.78
years) were less likely to express p53 protein (p-value=0.0341).
The hemoglobin level, hematocrit concentration, and white
blood cell count were signiﬁcantly lower in patients with
p53 expression (95.41 g/dL, 29.91%, 3.255×109/L, respectively)
than in patients without p53 expression (11.17 g/dL, 33.86%
and 5.236×109/L, respectively) (p-value<0.05).on. There was no progression to AML.
While some clinical characteristics seemed to correlate
with p53 expression, there were no statistically signiﬁcant dif-
ferences in p53 expression in relation to gender,MDSduration,
or chromosomal aberrations (p-value>0.05). The mean cor-Figure 1 – Strong staining (40%) of the p53 protein in bone
marrow (streptavidin–biotin – magniﬁcation: 400×).
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Figure 2 – Inﬂuence of the p53 expression on the reticulin and bone marrow iron in myelodysplastic patients at diagnosis.
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Figure 3 – Event-free survival curve of patients with low risk myelodysplastic syndrome and positive or negative for p53.
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eoreover, the IPSS-R classiﬁcations for all patients in this
tudy were low or very low and the difference between these
wo categories showed no signiﬁcant correlation with the p53
xpression. However, using the original IPSS criteria, most
atients negative for p53 (92%) were stratiﬁed in the low risk
ategorywhile only 53.8%of patientswithp53 expressionwere
ncluded in this category (p-value=0.011).
At the time of this study, none of the patients were
eceiving chemotherapy, except for those who progressed
o AML during the study. These patients were treated with
ypomethylation agents (azacitidine) and/or an immunomod-
lator (lenalidomide) during disease progression. Only one
atient, who was negative for p53, was treated with azaciti-
ine for severe isolated thrombocytopenia. This patient did
ot progress to AML.
Figure 2 shows p53 expression in relation to reticulin, a
arker for ﬁbrosis, and bone marrow iron in the sample.
atients with p53 expression had a higher frequency of more
dvanced ﬁbrosis levels (II/III) at diagnosis (46.15%), while the
atients without p53 expression showed a signiﬁcantly lower
requency (12%; p-value=0.041). Furthermore, patients with
53 expression also showed higher bone marrow iron at diag-
osis compared to patients without p53 expression (27.3%
ersus 5.5%, respectively). While this observation was not sta-
istically signiﬁcant, there was a marked tendency for bone
arrow iron to be higher when p53 was expressed.
In the group of patients expressing p53, two died and one
rogressed to AML (progression time: two months). On the
ther hand, in the group of patients without p53 expression,
nly one progressed to AML 30 months after diagnosis. The
edian follow-up time was 31 months after diagnosis, ran-ing from9 to 94months (interquartile range: 16–44.5months).
nalysis of combined, event-free survival (i.e. progression to
ML or disease-related death) showed that patients with p53
xpression had a signiﬁcantly lower median survival timecompared to patients without p53 expression, 18.5 and 32.5
months, respectively (p-value=0.046) (Figure 3).
Discussion
Despite the utility of scoring systems, such as the IPSS, it is
difﬁcult to consider all the variables that contribute to the
prediction of patient prognosis by using a single test. Other
clinical features, such as the presence of comorbidities,10 as
well as altered levels of ferritin, 2-microglobulin, and albu-
min in the blood11–13 can all have a signiﬁcant inﬂuence on
patient health and survival. Furthermore, the most notable
element missing from the commonly used prognostic scoring
systems is the identiﬁcation of speciﬁc molecular genetic fea-
tures, particularly mutations of individual genes.
The prognostic signiﬁcance of some recently described
mutations, such as TET2,14 EZH2,15 SF3B1,16 IDH1/IDH2,17 and
DNMT3A18 inMDS remains unclear, butmutations in TP53, the
gene encoding the p53 protein, have been consistently asso-
ciated with the complex karyotypes involved in complete or
partial deletion of chromosome 7 (−7/7q−) and chromosome
5 (−5/5q−) and appear to predict poor patient outcome. The
tumor suppressor TP53 gene is located on the short arm of
chromosome 17, and its p53 protein product has been directly
related to cell cycle regulation and apoptosis induction.19 The
active form of p53 has a very short half-life (approximately
6min), making it extremely difﬁcult to detect. In contrast,
mutated or inactive forms of the protein tend to accumulate
in the cell nucleus and can be easily detected by immuno-
logical methods such as immunohistochemistry.20 Thus, high
levels of accumulated p53 protein are associated with muta-
tions in TP53 and, consequently, the stopping of the cell cycle,
uncontrolled cell proliferation, and the appearance of addi-
tional genetic mutations. Each of these mechanisms could be
oter.
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expected to contribute to the progression of MDS as well as to
resistance to therapy.21
Furthermore, mutations in the TP53 gene have frequently
been reported in MDS patients with high risk IPSS; how-
ever, in groups at lower risk, this correlation has rarely been
found.22–24 In a study conducted by Jädersten et al.,25 an
association was found between the immunohistochemical
expression of p53 and TP53 mutations; this was corroborated
by Kulasekararaj et al.26 Moreover, the authors demonstrated
that mutations in the TP53 gene in patients with MDS, even
those classiﬁed as low risk, are related to poor treatment
response and disease progression. Additionally, these muta-
tions often occur early in the clinical course of the disease,
rarely appearing in more advanced cases.27
In the present study, the frequency of p53 expression
at diagnosis was 34.21%. These patients showed features
of poor prognosis, such as more advanced age at diagnosis
and lower hemoglobin levels, hematocrit concentrations, and
leukocyte counts, as well as advanced levels (II/III) of ﬁbro-
sis. Furthermore, the incidence of leukemic transformation
was signiﬁcantly higher in patients expressing p53 than those
who were p53 negative. Our ﬁndings are similar to previous
studies indicating that p53 expression can provide prognostic
information for MDS patients regarding the development of
acute leukemia and survival.9,26,27 However, to our knowledge,
this is the ﬁrst study that reports the initial at-diagnosis clini-
cal features and treatments associated with p53 expression of
patients with low-risk MDS.
Currently, p53 expression is not considered during MDS
prognosis scoring. Although the present study only focused on
low-risk patients, p53 expression at diagnosis helped identify
distinct clinical and laboratory proﬁles in this group, indicat-
ing that p53 immunohistochemical analysis in MDS patients
may be an important prognostic tool and should be consid-
ered for auxiliary analysis when determining the therapeutic
options for a patient. Furthermore, the previously described
immunohistochemical sensitivity of p53 in predicting the
presence of TP53 mutations22 is encouraging and developing
these types of methodologies for routine diagnostic analysis
will help advance our understanding of the diseases associ-
ated with MDS.
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